Loading DXCM detail
Loading ticker data...
Loading DXCM detail
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators.
DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Chart data unavailable
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Exchange Traded Concepts LLC lessened its position in shares of DexCom, Inc. (NASDAQ: DXCM) by 80.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,000 shares of the medical device company's stock after selling 8,031 shares during the period. Exchange Traded Concepts
Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability. Volatility and Risk Pacific Biosciences of California
Banque Pictet and Cie SA boosted its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 58.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,823 shares of the medical device company's stock after purchasing an additional 40,411 shares during the
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will hold a conference call to review the company's first quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.
Beacon Investment Advisory Services Inc. reduced its stake in DexCom, Inc. (NASDAQ: DXCM) by 12.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 272,836 shares of the medical device company's stock after selling 37,468 shares during the period. Beacon Investment
DexCom (NASDAQ: DXCM - Get Free Report) and LENSAR (NASDAQ: LNSR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Volatility and Risk DexCom has a beta of 1.48, suggesting
Sysmex (OTCMKTS:SSMXY - Get Free Report) and DexCom (NASDAQ: DXCM - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership. Profitability This table compares Sysmex and DexCom's net margins, return
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Gradient Investments LLC boosted its holdings in DexCom, Inc. (NASDAQ: DXCM) by 13.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 332,006 shares of the medical device company's stock after purchasing an additional 40,343 shares during the period. Gradient Investments LLC owned about
The Touchstone Sands Capital Select Growth Fund (Class A Shares, Load Waived) underperformed its benchmark, the Russell 1000® Growth Index, for the quarter ended December 31, 2025. Security selection weighed on relative performance across all seven sectors in the Fund, with the largest impact from Health Care, Information Technology, and Communication Services. The Fund's results stood in contrast to the broader market, which saw a sharp reversal in high-momentum segments.
DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.
Cinctive Capital Management LP purchased a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 66,148 shares of the medical device company's stock, valued at approximately $4,451,000. A number of other institutional investors have also added to
Bamco Inc. NY decreased its holdings in DexCom, Inc. (NASDAQ: DXCM) by 18.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 272,500 shares of the medical device company's stock after selling 60,000 shares during the period. Bamco Inc. NY
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
